TG Therapeutics (NASDAQ:TGTX) Price Target Raised to $49.00 at HC Wainwright

TG Therapeutics (NASDAQ:TGTX) had its price objective raised by stock analysts at HC Wainwright from $45.00 to $49.00 in a research report issued on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price target points to a potential upside of 197.33% from the company’s previous close.

A number of other research analysts also recently weighed in on the company. JPMorgan Chase & Co. reissued an “overweight” rating and issued a $25.00 price target on shares of TG Therapeutics in a research note on Thursday, April 18th. StockNews.com lowered shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, February 24th. The Goldman Sachs Group lifted their price target on TG Therapeutics from $12.00 to $13.00 and gave the company a “neutral” rating in a research note on Thursday, February 29th. B. Riley increased their price objective on TG Therapeutics from $24.00 to $29.00 and gave the stock a “buy” rating in a report on Monday, February 5th. Finally, LADENBURG THALM/SH SH upped their price objective on TG Therapeutics from $39.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $29.83.

TG Therapeutics Price Performance

Shares of TG Therapeutics stock traded up $0.60 during trading on Thursday, reaching $16.48. The company’s stock had a trading volume of 5,505,875 shares, compared to its average volume of 4,296,978. The stock has a 50-day moving average price of $15.13 and a two-hundred day moving average price of $14.33. The stock has a market capitalization of $2.55 billion, a P/E ratio of 828.91 and a beta of 2.33. The company has a current ratio of 5.92, a quick ratio of 5.18 and a debt-to-equity ratio of 0.62. TG Therapeutics has a one year low of $6.46 and a one year high of $35.67.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.02). TG Therapeutics had a net margin of 5.42% and a return on equity of 12.89%. The firm had revenue of $63.47 million during the quarter, compared to the consensus estimate of $54.60 million. During the same quarter in the prior year, the business earned ($0.28) EPS. TG Therapeutics’s revenue was up 713.5% on a year-over-year basis. As a group, sell-side analysts anticipate that TG Therapeutics will post -0.11 EPS for the current fiscal year.

Insiders Place Their Bets

In other TG Therapeutics news, Director Laurence N. Charney sold 22,000 shares of the stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $15.97, for a total transaction of $351,340.00. Following the transaction, the director now owns 215,229 shares in the company, valued at approximately $3,437,207.13. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 9.20% of the company’s stock.

Institutional Trading of TG Therapeutics

Several large investors have recently modified their holdings of the stock. Commonwealth Equity Services LLC boosted its stake in TG Therapeutics by 19.6% in the third quarter. Commonwealth Equity Services LLC now owns 182,400 shares of the biopharmaceutical company’s stock valued at $1,525,000 after buying an additional 29,878 shares in the last quarter. Raymond James & Associates boosted its stake in TG Therapeutics by 2.9% in the third quarter. Raymond James & Associates now owns 150,190 shares of the biopharmaceutical company’s stock valued at $1,256,000 after buying an additional 4,176 shares in the last quarter. Stratos Wealth Partners LTD. acquired a new stake in TG Therapeutics in the third quarter valued at about $87,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in TG Therapeutics by 11.9% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 26,412 shares of the biopharmaceutical company’s stock valued at $221,000 after buying an additional 2,805 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in TG Therapeutics by 25.2% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 85,580 shares of the biopharmaceutical company’s stock valued at $715,000 after buying an additional 17,207 shares in the last quarter. 58.58% of the stock is owned by institutional investors and hedge funds.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.